These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Risks and benefits of gene therapy. Noguchi P N Engl J Med; 2003 Jan; 348(3):193-4. PubMed ID: 12529458 [No Abstract] [Full Text] [Related]
3. For gene therapy, now-quantified risks are deemed troubling. Twombly R J Natl Cancer Inst; 2003 Jul; 95(14):1032-3. PubMed ID: 12865444 [No Abstract] [Full Text] [Related]
4. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. Hacein-Bey-Abina S; von Kalle C; Schmidt M; Le Deist F; Wulffraat N; McIntyre E; Radford I; Villeval JL; Fraser CC; Cavazzana-Calvo M; Fischer A N Engl J Med; 2003 Jan; 348(3):255-6. PubMed ID: 12529469 [No Abstract] [Full Text] [Related]
5. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Shou Y; Ma Z; Lu T; Sorrentino BP Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11730-5. PubMed ID: 16864781 [TBL] [Abstract][Full Text] [Related]
6. Medicine. Gene therapy--new challenges ahead. Williams DA; Baum C Science; 2003 Oct; 302(5644):400-1. PubMed ID: 14563994 [TBL] [Abstract][Full Text] [Related]
7. Gene therapy for severe combined immunodeficiencies. Gaspar HB; Thrasher AJ Expert Opin Biol Ther; 2005 Sep; 5(9):1175-82. PubMed ID: 16120048 [TBL] [Abstract][Full Text] [Related]
8. Gene therapy for severe combined immunodeficiency: are we there yet? Cavazzana-Calvo M; Fischer A J Clin Invest; 2007 Jun; 117(6):1456-65. PubMed ID: 17549248 [TBL] [Abstract][Full Text] [Related]
9. Is retroviral gene marking too dangerous to use? Brenner MK; Heslop HE Cytotherapy; 2003; 5(3):190-3. PubMed ID: 12850996 [No Abstract] [Full Text] [Related]
11. Efficacy of gene therapy for SCID is being confirmed. Cavazzana-Calvo M; Fischer A Lancet; 2004 Dec 18-31; 364(9452):2155-6. PubMed ID: 15610783 [No Abstract] [Full Text] [Related]
13. Progress toward the genetic treatment of the beta-thalassemias. Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654 [TBL] [Abstract][Full Text] [Related]
14. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000 [TBL] [Abstract][Full Text] [Related]
15. Gene therapy of primary T cell immunodeficiencies. Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M Gene; 2013 Aug; 525(2):170-3. PubMed ID: 23583799 [TBL] [Abstract][Full Text] [Related]
16. [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome]. Fischer A; Hacein-Bey-Abina S; Lagresle C; Garrigue A; Cavazana-Calvo M Bull Acad Natl Med; 2005 May; 189(5):779-85; discussion 786-8. PubMed ID: 16433450 [TBL] [Abstract][Full Text] [Related]